tbuckley/cabot-search huggingface dataset:
Ketogenic diets as an adjuvant therapy in glioblastoma (KEATING): A mixed methods randomised feasibility study
Authors: Kirsty Martin-McGill, Gemma Cherry, Anthony Marson, Catrin Tudur Smith, Bridget Young, Michael Jenkinson
Journal: Neuro-Oncology (2019)

Abstract Background There is increasing interest in the use of ketogenic diets (KD) as adjuvant therapy for glioblastoma (GBM). Trial aims: i) investigate protocol feasibility; ii) assess patient/carer acceptability; iii) explore the decision-making of patients’ invited to participate in KEATING; and iv) inform phase III trial design. Methods Prospective, feasibility study, with embedded qualitative design randomised 12 newly-diagnosed GBM patients to three months of medium chain triglyceride ketogenic diet (MCTKD) or the modified ketogenic diet (MKD) during chemoradiotherapy. Primary outcome was retention; secondary outcomes included recruitment rate, dietary acceptability, progression free survival (PFS) and overall survival (OS). Semi-structured interviews were conducted with a representative sample of patients and relatives (n=15). Results Recruitment targets were achieved, but recruitment rate was low (28.6%). Retention was poor; only 4 of 12 completed the three-month diet (MCTKD n=3; MKD n=1). Median duration until discontinuing was 5.2 weeks (0–7 weeks; n=8). Participants made instantaneous decisions without deliberation: relatives supported diet implementation. Decliners made considered decisions factoring diet burden and quality of life. A three-month diet was undesirable to these patients. Median PFS was 11.4 weeks and OS was 67.3 weeks. Conclusion Recruitment to a ketogenic-glioblastoma trial is possible. To assess effectiveness in a phase III clinical trial, a six week intervention period is proposed. Future trials should optimise and adequately support the decision-making of patients. The role of relatives should not be underestimated.
CALEB HILLIER PARRY (1755-1822)
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
POPULAR FALLACIES REGARDING ATHLETES AND ATHLETICS
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of brefeldin a on transcytotic vesicular pathway and bile secretion: A study on the isolated perfused rat liver and isolated rat hepatocyte couplets
Authors: D ALVARO
Journal: Hepatology (1995)

This study investigated the effect of Brefeldin A (BFA) on the transcytotic vesicular pathway labeled with horseradish peroxidase (HRP) in both isolated rat hepatocyte couplets (IRHC) and the isolated perfused rat liver (IPRL). To evaluate the role of the transcytotic vesicular pathway on bile secretion, the efffect of BFA on bile secretion in the IPRL was then investigated. In the basolateral area of IRHC, BFA showed no effect on the density and percentage of area of HRP-labeled vesicles. However, HRP-labeled vesicles tended to accumulate in the juxtanuclear area of BFA-treated hepatocytes (P < .001 vs. controls). In the pericanalicular area, on the other hand, HRP-labeled vesicles were depleted compared with controls (P < .001). In keeping with these findings, although the early peak remained unchanged, BFA inhibited as much as 50% of the late peak of HRP excretion in bile, after a pulse load of HRP in the IPRL. Bile flow and the biliary secretion of bile salts (BS) and phospholipids were not modified by BFA in isolated livers perfused without BS in the perfusate or with 1 μmol/min taurocholate (TCA). In BFA-treated livers, peak bile flow and BS output decreased by 20% (P < .05 vs. controls) only when a 5 μmol TCA bolus was administered. In conclusion, this study demonstrates that BFA inhibits the transcytotic vesicular pathway in the liver. However, BFA has no significant effect on bile secretion either in basal conditions or during perfusion with physiological amounts of BS. BFA slightly decreases bile flow and BS output only after an overload of BS, providing evidence against the physiological relevance of the transcytotic vesicular pathway in the process of bile formation. (HEPATOLOGY 1995;21:450–459.)
THE TREATMENT OF SYPHILIS IN ITS RELATION TO PREVENTION
Journal: JAMA (1929)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Report on M, Pasteur's Researches on Rabies and the Treatment of Hydrophobia by Preventive Inoculation
Authors: M. W. Vignal
Journal: BMJ (1886)

PREPARATION OF THE INOCULATING FLUID.-Theinoculating fluid used by NI.Pasteur is prepared as follows.The bottles containing dry air, in which are preserved the rabid spinal cords taken from rabbits, are arranged, according to date, on a table in a room where the air is not disturbed.The assistant, whose duty it is to prepare the inocu- lating fluid and fill the syringes, takes the cords, one by one, from the bottles, by drawing up the strings by which they are suspended.The cords and the strings are passed through the flame of a spirit.lamp, in order to destroy any germs that might have been deposited on them whilst the bottle was being opened.The threads are then cut, and the cords fall into a glass receptacle.These are then pounded by using a glass rod, and veal-broth is added in quantity equal to four or five times the volume of the cord before it was dried.The fluid, thus prepared, is turbid.The glass receptacle containing this fluid is covered by a paper which has been sterilised by heat.The receptacle, the glass rod, and the broth, used in preparing the inoculation-fluid, are previously carefully sterilised.Rabbits Inoculated.-Rabbits are inoculated in the following manner, and their spinal cords are subsequently used to prepare the fluid above described.The animal is secured on a board, its back upwards.A portion of its fur is cut away from its head ; the skin is then incised, and one of the temporal bones is pierced by means of a trephine about six millimetres in diameter, with very fine teeth.This instru- ment is used so as to prevent the centre-pin fiom entering the brain, or the crown from injuring it or the dura mater.When the piece of bone has been removed, some drops of the rabid virus are injected into the arachnoid membrane.For this, a Pravaz's syringe is used, the needle of which is bent at a right angle.The dura mater is pene- trated by the needle, and it reaches the arachnoid.The incision in the skin of the head is closed by a few sutures.M. Pasteur inoculated the first rabbit with virus taken from a mad dog.This virus was passed from rabbit to rabbit, and has been used, without interruption, for inoculations, up to the present time ITt is estimated that the virus has been passed through 130 rabbits.The incubation-period is rather less than seven days, as has been pre- viously stated.Antiseptic Precautions.-In trephining the rabbit's cra-nium, every antiseptic precaution is observed, and the instruments are sterilised.
Antimicrobial therapy
Authors: Luther Pat Rhodes
Journal: JAMA (1977)

<h3>To the Editor.—</h3> The Journalis to be congratulated for presenting the 18 guideline-audits for antimicrobial therapy. The Veterans Administration Ad Hoc Interdisciplinary Advisory Committee on Antimicrobial Drug Usage—Calvin M. Kunin, MD, Chairman (237:1001, 1977) outlined the purposes of the series and invited discussion. I suggest revision for two points: (1) the dosage schedule for meningococcal exposure prophylaxis (237:1134, 1977) and (2) the requirement for dosage modification of the lincosamines in renal failure (237:1003 and 1482, 1977). The recommendation of rifampin, 500 mg daily for five days, is difficult to follow since the drug is currently available in 300-mg preparations. A dose of 600 mg twice daily for two days (or once daily for five days) seems more widely recommended and applicable. The use of minocycline hydrochloride must be reconsidered in light of current evidence of vestibular toxicity. A more convenient schedule might be that presented by Finley.<sup>1</sup> Individual
CADD-14. TARGETING THE CD200 CHECKPOINT FOR THE FIGHT AGAINST CENTRAL NERVOUS SYSTEM TUMORS
Authors: Michael Olin, Elisabet Ampudia-Mesias, Christopher A Pennell, Zhengming Xiong, Susan K Rathe, David A Largaespada, Christopher L Moertel, G Elizabeth Pluhar
Journal: Neuro-Oncology (2018)

Numerous ongoing clinical trials targeting immune checkpoints have failed to enhance survival in patients with CNS tumors. We are targeting a unique checkpoint, CD200, which controls the immune system through paired inhibitory and activation receptors. The CD200 checkpoint interferes with tumor-immune interactions through multiple mechanisms: i) CD200 is secreted from tumors inducing an immunosuppressive environment, ii) CD200 is upregulated in tumor-associated vascular endothelial cells, creating an immunological barricade around the tumor microenvironment. We are targeting the activation receptor with a peptide ligand (CD200AR-L) activates antigen-presenting cells, enhancing dendritic cell maturation, cytokine production and antigen specific T cell activation. Treatment with CD200AR-L significantly extends survival in two murine glioma models. Directing the immune system to “fight the tumor”, requires introduction of an antigen such as autologous or allogeneic tumor lysate for non-immunogenic tumors such as CNS tumors. In an ongoing pilot study treating companion dogs with high-grade glioma, patients receiving a canine specific CD200 peptide inhibitor in combination with the autologous tumor lysate vaccine increased median survival to 330 days, compared to 194 with lysate alone. Currently, 41% of the dogs are alive; the longest living dog is now 810 days post-surgery. 28% of dogs died of non-tumor related deaths. In contrast, 100% of the dogs in the tumor lysate-only group died of tumor recurrence. Furthermore, serum chemistry profiles and physical examinations showed that the peptide did not induce any systemic toxicity. Importantly, we have developed human CD200 peptide ligands that enhance cytokine secretion, dendritic cell maturation, and antigen-specific immune response. This innovative research may provide a significant breakthrough for the field of cancer immunotherapy. We have also demonstrated that the use of a CD200AR-L in a murine breast carcinoma model resulted in a significant survival benefit. In this light, CD200AR-L may be a powerful immunotherapy platform for other solid tumors.
Abstract 547: Recombinant immunotoxins targeting B-cell maturation antigen induce complete responses in bone marrow myeloma mouse model
Authors: Zoe Shancer, Xiu-fen Liu, Emily King, Tapan Bera, Ira Pastan
Journal: Cancer Research (2019)

Abstract Background: Multiple myeloma (MM) is a B-cell malignancy for which new treatments are urgently needed. B-cell maturation antigen (BCMA) is a lineage-restricted differentiation protein highly expressed on MM and an ideal target for immunotherapy of MM. Recombinant immunotoxins (RITs) are chimeric proteins composed of the Fv or Fab portion of an antibody fused to a fragment of Pseudomonas Exotoxin A (PE). One of these, Lumoxiti, is FDA approved for the treatment of drug-resistant hairy cell leukemia, another B-cell malignancy. LMB-75 is an immunotoxin with an anti-BCMA dsFv of mAb BM306 fused to domain III of PE, and LMB-70 is an anti-BCMA Fab fused to domain III of PE. We previously treated H929 myeloma cells grown as subcutaneous tumors with anti-BCMA immunotoxins that are very effective in killing cultured cells and cells from patients. We observed tumor growth inhibition but not complete tumor responses. Goal: Here we used H929 cells to develop a bone marrow mouse model that is more relevant to human disease and to determine if these immunotoxins are more active against H929 cells growing in bone marrow. Methods: The NCI-H929 cell line was transfected with luciferase and GFP, recycled through the bone marrow of a mouse and enriched by flow to isolate cells with high GFP expression, which were used to inoculate tumors IV into NSG mice. Mice were treated IV with immunotoxins and tumor burden was assessed using bioluminescence imaging. Results: H929-luc-GFP cells grow uniformly in the bone marrow of mice, cause hind limb paralysis around day 40, and provide a relevant in vivo model for testing RITs. We achieved complete responses when treating mice with 1.5 mg/kg LMB-75 or LMB-70 given QODX5 beginning on days 4 or day 8. Mice in all treatment groups were disease free at 3 months. An immunotoxin targeting CD22, which is not expressed on H929 cells, or an anti-BCMA immunotoxin with a mutation that inactivates toxin activity did not have any anti-tumor activity. Conclusions: LMB-75 and LMB-70 induce complete, durable remissions of H929-luc-GFP cells growing in mouse bone marrow without toxicity to mice. These promising results support further pre-clinical development of these agents for MM. Citation Format: Zoe Shancer, Xiu-fen Liu, Emily King, Tapan Bera, Ira Pastan. Recombinant immunotoxins targeting B-cell maturation antigen induce complete responses in bone marrow myeloma mouse model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 547.
MORALE
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Eosinophilic cellulitis
Authors: G.C. Wells, Neil P. Smith
Journal: British Journal of Dermatology (1979)

Journal Article Eosinophilic cellulitis Get access G.C. Wells, G.C. Wells St Thomas' Hospital, Lambeth Palace Road, London SE17EH and St John's Hospital for Diseases of the Skin, Lisle Street, Leicester Square, London WC2H 7BJ Search for other works by this author on: Oxford Academic Google Scholar Neil P. Smith Neil P. Smith St Thomas' Hospital, Lambeth Palace Road, London SE17EH and St John's Hospital for Diseases of the Skin, Lisle Street, Leicester Square, London WC2H 7BJ Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 100, Issue 1, 1 January 1979, Pages 101–109, https://doi.org/10.1111/j.1365-2133.1979.tb03574.x Published: 01 January 1979
SAT0511 Practical suggestions on intravenous iloprost in raynaud’s phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus
Authors: T. Schioppo, F. Ingegnoli, Y. Allanore, R. Caporali, M. Colaci, O. Distler, D.E. Furst, N. Hunzelmann, F. Iannone, D. Khanna, M. Matucci-Cerinic
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Raynaud's phenomenon (RP) and digital ulcer (DU) are prominent features of SSc. According to the 2017 EULAR recommendations, intravenous (IV) iloprost (ILO) may be used for RP and DU after failure of oral therapies. Where available, IV ILO is indicated in RP secondary to systemic sclerosis (SSc) for 3–5 days with no other advice about the regimen (dosage, duration and frequency). <h3>Objectives</h3> To provide a systematic review focused on IV ILO use in SSc RP and DU and to perform a meta-analysis. In the case of lack of data, a Delphi consensus was performed to provide practical suggestions about ILO usage in SSc RP and DU and to propose a research agenda for future studies. <h3>Methods</h3> The systematic review of the literature on IV ILO in SSc patients complicated by DU and RP was performed according to PRISMA guidelines and the meta-analysis to the GRADE system. A three-step web-based Delphi consensus was designed if not enough data were available from the literature. <h3>Results</h3> The review flow process is outlined in figure 1. The meta-analysis could not be performed due to insufficient literature data about dosage, regimen and frequency of IV ILO. Therefore, a three-round Delphi exercise was performed to identify and establish a consensus about IV ILO use in SSc RP and DU. Expert consensus was reached at the third step for the following items: - Severe or refractory to oral therapy RP, IV ILO 0.5 and 2.0 ng/kg/min, 1–3 days monthly. - DU healing, IV ILO 0.5 and 2.0 ng/kg/min up to the maximum tolerated dose the first day of therapy, 1–3 days monthly. - DU prevention, IV ILO 0.5 and 2.0 ng/kg/min, 1 day monthly. - Research agenda: trials for head-to-head comparison and for regimen assessment. <h3>Conclusions</h3> IV ILO is currently available in some countries with the approved indication only for RP-SSc for 3–5 days. Our data, based on expert consensus, suggest a 1–3 days monthly regimen for RP and DU healing and 1 day monthly for DU prevention. These suggestions may allow clinicians to decide how to personalise the IV ILO therapy according to patients' needs. Although these suggestions are intended for clinical setting use, it will be necessary to formally validate the present suggestions in future clinical trials. <h3>Acknowledgements</h3> The consensus meeting has been supported by Italfarmaco. <h3>Disclosure of Interest</h3> None declared
Spontaneous Return and Facial Nerve Grafting
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal